The History of Urolithin A: From Gut Metabolite to Studied Supplement

Urolithin A feels like a recent discovery, but the story stretches back much further than its arrival on supplement shelves. It is a story about pomegranates, gut bacteria, a landmark mitochondrial finding, and the slow work of turning a natural metabolite into something measured in clinical trials.

The ancient ingredients, the modern question

Long before anyone had heard of urolithin A, the foods that give rise to it were prized across cultures. Pomegranates appear in ancient Mediterranean and Middle Eastern tradition as symbols of health and fertility; walnuts and berries have been dietary staples for millennia. For most of that time, their reputed benefits were attributed vaguely to the fruits themselves. The real story turned out to be more subtle: the benefit was not in the fruit directly, but in what the body — specifically the gut microbiome — does with it.

The raw materials are a class of polyphenols called ellagitannins, and their breakdown product ellagic acid. For a long time researchers were puzzled: ellagitannins and ellagic acid are poorly absorbed, so how could they be doing much good? The answer was that gut bacteria transform them into something else entirely. Our pages on ellagitannins and ellagic acid cover those precursors in detail.

Enter the urolithins

Over the latter decades of the twentieth century and into the 2000s, analytical chemists working on polyphenol metabolism identified the compounds that gut bacteria produce from ellagitannins. These were named urolithins — a family that includes urolithin A, urolithin B, and several related molecules — because they were first characterized in the context of metabolic and urinary studies of these dietary polyphenols. The key realization was that when people eat pomegranate or walnuts, what shows up in their system is largely not ellagic acid but these bacterial metabolites. Urolithin A emerged as the most studied member of the family. For the family tree, see urolithin A vs urolithin B.

One finding from this era still shapes the field today: not everyone produces urolithin A. Researchers studying human populations found that only a subset of people — often estimated at around a third — harbor the gut bacteria needed to convert ellagitannins into meaningful amounts of urolithin A. This “producer versus non-producer” divide became central to understanding why dietary studies gave inconsistent results, and it is the single best argument for why a standardized supplement exists at all. We cover it in are you a urolithin A producer?

2016: the landmark that changed everything

The turning point came in 2016, when Ryu and colleagues published a study in Nature Medicine that transformed urolithin A from a curiosity into a research priority. Working in laboratory models, they showed that urolithin A induced mitophagy — the cellular process of clearing out damaged mitochondria — and that this translated into extended lifespan in the worm C. elegans and improved muscle function in rodents. This was preclinical work (animal and cell, not human proof), but it provided a clear, compelling mechanism: here was a naturally derived compound that could prompt cells to clean house and renew their energy machinery. Suddenly urolithin A had a reason to be taken seriously by the aging-research community. Our what is mitophagy? page explains the process that put urolithin A on the map.

2019: the first human proof

A mechanism in worms and mice is a beginning, not an endpoint. The next milestone was translating it to people. In 2019, Andreux and colleagues published the first-in-human trial in Nature Metabolism. It established that urolithin A was safe and well tolerated at doses up to 1,000 mg per day and — crucially — produced a mitochondrial gene-expression signature in human muscle, echoing what had been seen in the lab. For the first time, there was direct evidence that the compound did something measurable in human cells.

The 2020s: building the human evidence base

With safety and mechanism established, the 2020s became the decade of functional outcomes. Liu, D'Amico and colleagues (2022, JAMA Network Open) reported improved muscle endurance in older adults over about four months. Singh and colleagues (2022, Cell Reports Medicine) reported improvements in muscle strength and exercise performance in middle-aged adults at 500 mg and 1,000 mg daily, cementing the clinically studied dose range. A 2024 trial in the Journal of the International Society of Sports Nutrition extended the research to resistance-trained men, and a 2025 randomized trial in Nature Aging reported support for immune-cell mitochondrial health in midlife adults — broadening the story from muscle toward the immune system and “inflammaging.” A 2024 systematic review in Ageing Research Reviews pulled the human evidence together. For the current state of play, see our 2026 research update.

In parallel, urolithin A moved from laboratory curiosity to commercial reality. A standardized, manufactured form of urolithin A was developed and brought to market, making a consistent dose available to people regardless of whether their own gut bacteria could produce it — solving, in effect, the producer/non-producer problem that had muddied decades of dietary research.

Where the history leaves us

In the span of a single decade, urolithin A went from a poorly understood byproduct of pomegranate digestion to one of the more clinically studied compounds in the longevity field, with human trials behind its core claims around mitochondrial and muscle health. The arc is a good reminder of how nutritional science actually works: a traditional food, a puzzling absorption problem, a microbiome insight, a mechanistic breakthrough, and then the patient accumulation of human trials. The story is still being written — much of the “beyond muscle” research remains preclinical — but the foundation is unusually solid for a natural compound. If you want to understand what that research supports today, start with our complete urolithin A guide or compare products in our best urolithin A gummies roundup.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This guide is educational and is not a substitute for advice from a qualified healthcare provider.